UNIGE document Professional Article
previous document  unige:83360  next document
add to browser collection

Médicaments génériques et biosimilaires : une panacée ?

Published in Revue médicale suisse. 2015, vol. 11, no. 490, p. 1909-1914
Abstract Drugs are the third largest source of expenditure under Switzerland's compulsory basic health insurance. Generics, the price of which should be at least 30 per cent less than the cost of the original drugs, can potentially allow substantial savings. Their approval requires bioequivalence studies and their use is safe, although some factors may influence patients' and physicians' acceptance. The increased substitution of biosimilar drugs for more expensive biotech drugs should allow further cost savings. In an attempt to extend the monopoly granted by the original drug patent, some pharmaceutical companies implement "evergreening" strategies including small modifications of the original substance for which the clinical benefit is not always demonstrated.
Keywords Biosimilar Pharmaceuticals/administration & dosage/economicsDrug CostsDrug Industry/economicsDrug Substitution/economicsDrugsGeneric/administration & dosage/economicsHumansPatents as TopicSwitzerland
PMID: 26665661
Full text
Article (Published version) (1 MB) - public document Free access
(ISO format)
DALY, Marie-Josée, GUIGNARD, Bertrand, NENDAZ, Mathieu. Médicaments génériques et biosimilaires : une panacée ?. In: Revue médicale suisse, 2015, vol. 11, n° 490, p. 1909-1914. https://archive-ouverte.unige.ch/unige:83360

317 hits



Deposited on : 2016-04-25

Export document
Format :
Citation style :